Monte Rosa Therapeutics
Yahoo Finance • last year
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside disc... Full story
Yahoo Finance • last year
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel... Full story
Yahoo Finance • last year
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Dru... Full story
Yahoo Finance • last year
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million... Full story
Yahoo Finance • last year
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients Monte Rosa to receive an upfront payment of $50 million and po... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in MYC-driven tumor cellsPhase 1/2 clinical trial of MRT-2359 ongoing in MYC-driven solid tumors, including lung... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fi... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in it... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcom... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers – – Novel and Proprietary AI/Machine Learning Engine Characterizes Protein Surfaces, Ex... Full story
Yahoo Finance • 2 years ago
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359,a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restri... Full story
Yahoo Finance • 3 years ago
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors – BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing nov... Full story
